N/A N=287 Examining the Effectiveness of Cognitive Training
Cognitive Change
Primary: Proportion of Correct Targets Identified Minus False Identifications in the n-Back Task — .80; .70; .68; .21 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=3,605 S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
Febrile Neutropenia · Stage 0 Breast Cancer · Stage 0 Colorectal Cancer
Primary: Percentage of Participants With CSF Prescribed as Primary Prophylaxis — 8.3; 5.5; 7.2; 5.3 percentage of participants — p=0.21
N/A N=29 Oxygen Reserve Index (ORi) Expanded Data Set Validation of INVSENSOR00029
Healthy
Primary: Concordance for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values — 99.4; 89.74; 89.86 percentage of accuracy
Phase 3 N=87 A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome
Dravet Syndrome
Primary: Change in Convulsive Seizure Frequency (CSF) From the Baseline Period (Baseline) to the Combined Titration + Maintenance (T+M) Period — -3.18; -0.65 Convulsive seizures…
Phase 3 N=262 A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome
Dravet Syndrome · Seizure Disorder
Primary: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8…
N/A N=44 An eHealth Psychosocial Intervention for Caregivers of Children With Cancer
Pediatric Cancer
Primary: The eSCCIP Evaluation Questionnaire — 3.53; 3.6; 3.76; 3.6 score on a scale
N/A N=29 Oxygen Reserve Index (ORi) Expanded Data Set Validation of INVSENSOR00025
Healthy
Primary: Concordance for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values. — 99.68; 92.94; 91.48 percentage of accuracy
N/A N=120 CompuFlo Thoracic Epidural Study
Thoracic Epidural Anesthesia
Primary: Number of Participants With Successful Thoracic Epidural Catheter Placement — 52; 58 Participants
Phase 2 N=59 Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Deleterious BRCA1 Gene Mutation · Deleterious BRCA2 Gene Mutation · Loss of Heterozygosity
Primary: Overall Response Rate — 8; 12 Percentage of participants
Phase 3 N=152 Phase 3 Alogliptin Pediatric Study
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 — -0.011; 0.091 percentage of HbA1c — p==0.782
Phase 4 N=324 Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
Chronic Heart Failure With Preserved Systolic Function
Primary: Effect of Dapagliflozin, as Compared With Placebo, on Heart Failure Related Health Status Using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Summary…
Phase 4 N=242 Primary Tube Versus Trabeculectomy Study
Glaucoma
Primary: Number of Participants With Surgical Failure — 31; 23; 18; 9 Participants
N/A N=1,959 Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women
HIV Infections
Primary: HIV-1 Seroconversion According to Comprehensive HIV Testing Algorithm. — 82; 61 Participants
N/A N=20 Cognition and Magnetic Resonance Imaging of Brain Inflammation in Obesity
Obesity
Primary: Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI) — .0468; .0492…
Phase 1 N=18 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
HER2 Positive Breast Carcinoma · Recurrent Breast Carcinoma · Stage III Breast Cancer
Primary: Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Dose-limiting toxicities (DLTs)